Literature DB >> 10377129

Biased immunoglobulin G1 isotype responses induced in cattle with DNA expressing msp1a of Anaplasma marginale.

A Arulkanthan1, W C Brown, T C McGuire, D P Knowles.   

Abstract

Immunization with the native major surface protein 1 (MSP1) (a heterodimer containing disulfide and noncovalently bonded polypeptides designated MSP1a and MSP1b) of the erythrocytic stage of Anaplasma marginale conferred protection against homologous challenge (G. H. Palmer, A. F. Barbet, W. C. Davis, and T. C. McGuire, Science 231:1299-1302, 1986). The MSP1a polypeptide possesses a conserved neutralization-sensitive epitope. In the present study, the immune response to DNA-mediated immunization using msp1a was studied. The plasmid pVCL/MSP1a, which encodes the complete msp1a gene of A. marginale under the control of human cytomegalovirus immediate-early enhancer/promoter and intron A, was constructed. The immune responses elicited by immunization with pVCL/MSP1a into cardiotoxin-induced regenerating muscle were evaluated in mice and cattle. Antibody reactive with native MSP1a was detected in pooled sera of immunized BALB/c mice 3 weeks following primary immunization. Two calves seronegative for A. marginale were immunized four times, at weeks 0, 3, 7, and 13, with pVCL/MSP1a. By 8 weeks, both calves responded to MSP1a with an antibody titer of 1:100, which peaked at 1:1,600 and 1:800 by 16 weeks after the initial immunization. Interestingly, immunoblotting with anti-immunoglobulin G1 (anti-IgG1) and anti-IgG2 specific monoclonal antibodies revealed a restricted IgG1 anti-MSP1a response in both animals. T-lymphocyte lines, established after the fourth immunization, proliferated specifically against A. marginale homogenate and purified MSP1 in a dose-dependent manner. These data provide a basis for an immunization strategy to direct bovine immune responses by using DNA vaccine vectors containing single or multiple genes encoding major surface proteins of A. marginale.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10377129      PMCID: PMC116534     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  53 in total

1.  Characterization of an immunoprotective protein complex of Anaplasma marginale by cloning and expression of the gene coding for polypeptide Am105L.

Authors:  A F Barbet; G H Palmer; P J Myler; T C McGuire
Journal:  Infect Immun       Date:  1987-10       Impact factor: 3.441

2.  Recognition of conserved surface protein epitopes on Anaplasma centrale and Anaplasma marginale isolates from Israel, Kenya and the United States.

Authors:  G H Palmer; A F Barbet; A J Musoke; J M Katende; F Rurangirwa; V Shkap; E Pipano; W C Davis; T C McGuire
Journal:  Int J Parasitol       Date:  1988-02       Impact factor: 3.981

3.  Characterization of a neutralization-sensitive epitope on the Am 105 surface protein of Anaplasma marginale.

Authors:  G H Palmer; S D Waghela; A F Barbet; W C Davis; T C McGuire
Journal:  Int J Parasitol       Date:  1987-10       Impact factor: 3.981

4.  Bovine leucosis virus contamination of a vaccine produced in vivo against bovine babesiosis and anaplasmosis.

Authors:  R J Rogers; C K Dimmock; A J de Vos; B J Rodwell
Journal:  Aust Vet J       Date:  1988-09       Impact factor: 1.281

5.  Molecular size variations in an immunoprotective protein complex among isolates of Anaplasma marginale.

Authors:  S M Oberle; G H Palmer; A F Barbet; T C McGuire
Journal:  Infect Immun       Date:  1988-06       Impact factor: 3.441

6.  Regeneration after cardiotoxin injury of innervated and denervated slow and fast muscles of mammals. Myosin isoform analysis.

Authors:  A d'Albis; R Couteaux; C Janmot; A Roulet; J C Mira
Journal:  Eur J Biochem       Date:  1988-05-16

7.  Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.

Authors:  T R Mosmann; H Cherwinski; M W Bond; M A Giedlin; R L Coffman
Journal:  J Immunol       Date:  1986-04-01       Impact factor: 5.422

8.  Immune serum against Anaplasma marginale initial bodies neutralizes infectivity for cattle.

Authors:  G H Palmer; T C McGuire
Journal:  J Immunol       Date:  1984-08       Impact factor: 5.422

9.  Immunization with an isolate-common surface protein protects cattle against anaplasmosis.

Authors:  G H Palmer; A F Barbet; W C Davis; T C McGuire
Journal:  Science       Date:  1986-03-14       Impact factor: 47.728

10.  Common and isolate-restricted antigens of Anaplasma marginale detected with monoclonal antibodies.

Authors:  T C McGuire; G H Palmer; W L Goff; M I Johnson; W C Davis
Journal:  Infect Immun       Date:  1984-09       Impact factor: 3.441

View more
  4 in total

1.  DNA vaccine construct incorporating intercellular trafficking and intracellular targeting motifs effectively primes and induces memory B- and T-cell responses in outbred animals.

Authors:  Waithaka Mwangi; Wendy C Brown; Gary A Splitter; Christopher J Davies; Chris J Howard; Jayne C Hope; Yoko Aida; Yan Zhuang; Beverly J Hunter; Guy H Palmer
Journal:  Clin Vaccine Immunol       Date:  2007-01-10

2.  Selective in vivo depletion of CD4(+) T lymphocytes with anti-CD4 monoclonal antibody during acute infection of calves with Anaplasma marginale.

Authors:  Reginald A Valdez; Travis C McGuire; Wendy C Brown; William C Davis; Jeffrey M Jordan; Donald P Knowles
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

Review 3.  Antigens and alternatives for control of Anaplasma marginale infection in cattle.

Authors:  Katherine M Kocan; José de la Fuente; Alberto A Guglielmone; Roy D Meléndez
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

4.  Epitope-based vaccines with the Anaplasma marginale MSP1a functional motif induce a balanced humoral and cellular immune response in mice.

Authors:  Paula S Santos; Angela A S Sena; Rafael Nascimento; Thaise G Araújo; Mirian M Mendes; João R S Martins; Tiago W P Mineo; José R Mineo; Luiz R Goulart
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.